Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Reports Q1 2025 Financial Results and Raises Revenue Guidance
Summary
Vertex Pharmaceuticals reported Q1 2025 financial results showing total revenue of $2.77 billion, a 3% increase compared to Q1 2024. The company raised the low end of its total revenue guidance by $100 million to a new range of $11.85 to $12 billion. Strong progress was noted with the launches of ALYFTREK, CASGEVY, and JOURNAVX. ALYFTREK is approved in the U.S. and U.K. for cystic fibrosis, CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, and JOURNAVX for moderate-to-severe acute pain.
Profitelligence Alerts
Get alerts for VRTX
Be first to know when Vertex Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.
Official SEC Documents
Advertisement